CYCLO THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.4 USD | +2.19% |
|
-4.76% | -11.95% |
| 05-01 | HC Wainwright Starts Cyclo Therapeutics With Buy Rating, $3 Price Target | MT |
| 03-18 | Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Evolution of the average Target Price on Cyclo Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
70de7a0a42b96f859e2152a.Fuj54CT4h9ivrhgI57dRZrJAf49k_xT73aJUZppxfmg.YKKOlxyXtare5kJ9kc01D_kpEs0hjXqWh_Y3UvYaU1kkgIiaRpbdi-DKew~a6a6dce646edb3eee94de828ca118174
More recommendations
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.4
USD
Average target price
3.2
USD
Spread / Average Target
+128.57%
High Price Target
4
USD
Spread / Highest target
+185.71%
Low Price Target
2.6
USD
Spread / Lowest Target
+85.71%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Cyclo Therapeutics, Inc.
| HC Wainwright | |
| Maxim |
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
- Stock Market
- Equities
- CYTH Stock
- Consensus Cyclo Therapeutics, Inc.
